Literature DB >> 3993789

Postprandial regulation of renal hemodynamics: role of pancreatic glucagon.

A J Premen, J E Hall, M J Smith.   

Abstract

The aim of this study was to ascertain the quantitative importance of glucagon in mediating protein-induced increases in renal blood flow (RBF) and glomerular filtration rate (GFR) during the postprandial state. Six chronically instrumented conscious dogs were each subjected to four protocols: normal protein control meal (C); high protein meat meal (M); somatostatin infusion and meat (S + M); and glucagon infusion. C produced small increases in RBF (12 +/- 2%) and GFR (14 +/- 2%) without changing arterial plasma glucagon. M produced marked increases in RBF (38 +/- 4%), GFR (41 +/- 5%), and glucagon (from 23.3 +/- 3.6 to 73.3 +/- 7.1 pg/ml) over a 3-h period. During S + M, RBF and GFR failed to increase while glucagon was suppressed by 36 +/- 8% over a 2-h period. When S was stopped, glucagon rose to 100 +/- 13.9 pg/ml over the next hour, yet RBF and GFR increased by only 14 +/- 4 and 10 +/- 3%, respectively. Glucagon infusion (3 ng X kg-1 X min-1, i.v.) markedly elevated plasma glucagon to 131.6 +/- 27.3 pg/ml, yet neither RBF nor GFR significantly changed. These data indicate that while a protein-rich meat meal does elevate arterial plasma glucagon, the rise is not great enough to elicit significant changes in renal hemodynamics. Thus, elevated plasma levels of glucagon cannot account for protein-mediated increases in RBF and GFR during the postprandial state.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3993789     DOI: 10.1152/ajprenal.1985.248.5.F656

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Glucagon receptor-mediated extracellular signal-regulated kinase 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C.

Authors:  Xiao C Li; Oscar A Carretero; Yuan Shao; Jia L Zhuo
Journal:  Hypertension       Date:  2006-01-03       Impact factor: 10.190

2.  Postprandial changes in portal haemodynamics in patients with cirrhosis.

Authors:  S O'Brien; M Keogan; S Patchett; P A McCormick; N Afdhal; J E Hegarty
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

3.  Dopamine D2-like receptors and amino acid-induced glomerular hyperfiltration in humans.

Authors:  G Luippold; S Schneider; A Stefanescu; P Benöhr; B Mühlbauer
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 4.  Glomerular function reserve and sodium sensitivity.

Authors:  Genjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

5.  Influence of hepatic innervation on renal glomerular filtration rate.

Authors:  F Lang; I Ottl; D Häussinger
Journal:  Pflugers Arch       Date:  1993-11       Impact factor: 3.657

6.  Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice.

Authors:  Xiao C Li; Tang-Dong Liao; Jia L Zhuo
Journal:  Clin Sci (Lond)       Date:  2008-05       Impact factor: 6.124

7.  Evidence for renal kinins as mediators of amino acid-induced hyperperfusion and hyperfiltration in the rat.

Authors:  A A Jaffa; C P Vio; R H Silva; R J Vavrek; J M Stewart; P F Rust; R K Mayfield
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

8.  Functional response of healthy and diseased glomeruli to a large, protein-rich meal.

Authors:  A Y Chan; M L Cheng; L C Keil; B D Myers
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

9.  Renal effects of gastrin C-terminal tetrapeptide (as pentagastrin) and cholecystokinin octapeptide in conscious rabbit and man.

Authors:  J Calam; D Gordon; W S Peart; S A Taylor; R J Unwin
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

Review 10.  Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Clin Sci (Lond)       Date:  2007-08       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.